| SCYNEXIS INC. DL -,001 |
| USA |
| US8112923094 / A42CF6 |
| 135 (Frankfurt) / SCYX (NASDAQ) |
| FRA:135, ETR:135, 135:GR, NASDAQ:SCYX |
| - |
| - |
|
SCYNEXIS, Inc. Common Stock represents the equity of SCYNEXIS, Inc., a biotechnology company focused on developing therapies for difficult-to-treat and drug-resistant fungal infections as well as certain severe rare diseases. The company markets BREX..
>Volltext.. |
| 38.34 Mio. EUR |
| -7.5 Mio. EUR |
| 16.87 Mio. EUR |
| -19.84 Mio. EUR |
| -8.98 Mio. EUR |
| -1.62 EUR |
| 1.71 Mio. EUR |
| 9.28 Mio. EUR |
| -11.68 Mio. EUR |
| 9.3 |
| 489.78% |
| 47.56% |
| - |
| - |
| - |
| - |
| 29.09.26 |
|